Proprietary Drug Discovery Platform
Condensate drug discovery at the molecular level
Advancing therapeutics that address intractable targets via condensates.
Transition Bio is built on technology and IP from the Weitz lab at Harvard University and the Knowles lab at University of Cambridge.
Delivering definitive data…
Our platform provides the molecular lens required to capitalize on the promise of condensate biology. Learn More >
…by targeting well-defined biology…
Pursue intractable targets via well-defined condensates with specific therapeutic hypothesis. Example: Dissolve RNA foci to release sequestered RNA splicing factors (rare genetic disease). Learn More >
…with our differentiated molecular platform.
Drive drug discovery by identifying and selecting novel & optimal binding MOA(s). Example: Structured binding pocket on protein that regulates MYC (multiple cancers). Learn More >
News And Events
What’s new at Transition Bio
Transition Bio, Inc., a microfluidics- driven drug discovery platform company using biophysical…
Transition Bio, Inc. (the Company) today named several critical additions to its leadership team, including naming Gregory Miller as CEO…
